Molecular Cancer

Article	Citations
Correction to: The function and mechanisms of action of circular RNAs in Urologic Cancer	1703
Tumor microenvironment dynamics in gastric cancer pathogenesis and therapeutic resistance	912
SOS1: tracking the evolving path from promising to actionable therapeutic target in RAS-dependent cancers	891
The construction of modular universal chimeric antigen receptor T (MU-CAR-T) cells by covalent linkage of allogeneic T cells and various antibody fragments	783
Genome-wide CRISPR screening identifies tyrosylprotein sulfotransferase-2 as a target for augmenting anti-PD1 efficacy	752
E3 ubiquitin ligase MAGI3 degrades c-Myc and acts as a predictor for chemotherapy response in colorectal cancer	675
Spatial and functional dissection of cancer-associated fibroblasts-mediated immune modulation in H. pylori-associated gastric cancer	586
LMTK3 regulation of EV biogenesis and cargo sorting promotes tumour growth by reducing monocyte infiltration and driving pro-tumourigenic macrophage polarisation in breast cancer	566
Engineered multifunctional nanoparticles for enhanced radiation therapy: three-in-one approach for cancer treatment	540
Correction: m6A demethylase ALKBH5 inhibits tumor growth and metastasis by reducing YTHDFs-mediated YAP expression and inhibiting miR-107/LATS2–mediated YAP activity in NSCLC	474
KRAS and MYC synergistic inhibition: a powerful strategy targeting KRAS-mutant cancers	398
Retraction Note: Epigenetic modification of ferroptosis by non-coding RNAs in cancer drug resistance	391
BRD9-p53-E2F1 circuit orchestrates cell growth and DNA damage repair in gastric cancer	376
The miR-23a/27a/24 − 2 cluster drives immune evasion and resistance to PD-1/PD-L1 blockade in non-small cell lung cancer	355
Intercellular TIMP-1-CD63 signaling directs the evolution of immune escape and metastasis in KRAS-mutated pancreatic cancer cells	328
Polyamine and EIF5A hypusination downstream of c-Myc confers targeted therapy resistance in BRAF mutant melanoma	305
Immunotherapies in rare cancers	305
The epigenetic regulatory mechanism of PIWI/piRNAs in human cancers	295
Exosomal circSIPA1L3-mediated intercellular communication contributes to glucose metabolic reprogramming and progression of triple negative breast cancer	284
The circular RNA circHMGB2 drives immunosuppression and anti-PD-1 resistance in lung adenocarcinomas and squamous cell carcinomas via the miR-181a-5p/CARM1 axis	278
The puppet master in the breast cancer “microecological community”: spatial and metabolic regulation of macrophage heterogeneity	272
Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers	260
Traditional Chinese medicine for the treatment of cancers of hepatobiliary system: from clinical evidence to drug discovery	246
LINC02159 promotes non-small cell lung cancer progression via ALYREF/YAP1 signaling	243
TGF-β signaling promotes cervical cancer metastasis via CDR1as	242

Proteogenomic characterization of molecular and cellular targets for treatment-resistant subtypes in locally advanced cervical cancers	232
Neoadjuvant immunotherapy in squamous cell carcinoma of the head and neck: current evidence and future perspectives	231
Advances in RNA-based cancer therapeutics: pre-clinical and clinical implications	226
JUN mediates the senescence associated secretory phenotype and immune cell recruitment to prevent prostate cancer progression	220
circNOX4 activates an inflammatory fibroblast niche to promote tumor growth and metastasis in NSCLC via FAP/IL-6 axis	217
Development and validation of a small extracellular vesicle-derived RNA signature for early diagnosis of lung adenocarcinoma and prognosis in advanced stages	210
STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway	209
ERK mediates interferon gamma-induced melanoma cell death	201
Chaperone-mediated autophagy modulates Snail protein stability: implications for breast cancer metastasis	200
The CD47/TSP-1 axis: a promising avenue for ovarian cancer treatment and biomarker research	200
Increased plasma concentrations of acyl-coenzyme A binding protein (ACBP) predict future lung cancer development in smokers at risk of cardiovascular disease	199
LncRNA PVT1 in human cancers: genomic complexity, isoforms, functional elements, mechanism of action, subcellular localization and possible role as a therapeutic target	196
Myofibroblast-derived extracellular vesicles facilitate cancer stemness of hepatocellular carcinoma via transferring ITGA5 to tumor cells	194
Letter to the Editor: An ultra-sensitive assay using cell-free DNA fragmentomics for multi-cancer early detection	193
PIK3CA mutations-mediated downregulation of circLHFPL2 inhibits colorectal cancer progression via upregulating PTEN	193
Emerging roles of tRNA-derived fragments in cancer	189
Nanotechnology-leveraged CRISPR/Cas systems: icebreaking in trace cancer-related nucleic acids biosensing	188
Gold nanoparticles and gold nanorods in the landscape of cancer therapy	182
Correction: YTHDF2 in peritumoral hepatocytes mediates chemotherapy-induced antitumor immune responses through CX3CL1-mediated CD8+ T cell recruitment	181
Correction: Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p/snail/DPP4 axis	181
Biomarker-empowered precision navigation of CAR-T cell therapy	179
Biomolecular phase separation in tumorigenesis: from aberrant condensates to therapeutic vulnerabilities	178
Context-dependent effect of glucocorticoid receptor activity shapes ovarian cancer cell plasticity and therapy response	176
Nuclear receptors as novel regulators that modulate cancer radiosensitivity and normal tissue radiotoxicity	175
Therapy-induced senescent tumor cell-derived extracellular vesicles promote colorectal cancer progression through SERPINE1-mediated NF-κB p65 nuclear translocation	173
Bidirectional role of neutrophils in tumor development	172
Biofilm formation by the host microbiota: a protective shield against immunity and its implication in cancer	170
Tumor cell-intrinsic MELK enhanced CCL2-dependent immunosuppression to exacerbate hepatocarcinogenesis and confer resistance of HCC to radiotherapy	166
Efferocytosis: the art of cellular clearance and novel perspectives in disease therapy	161
Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments	160
Effects of RNA methylation on Tumor angiogenesis and cancer progression	157
Molecular mechanisms and therapeutic significance of Tryptophan Metabolism and signaling in cancer	155
NK cells are never alone: crosstalk and communication in tumour microenvironments	153
LINC00115 promotes chemoresistant breast cancer stem-like cell stemness and metastasis through SETDB1/PLK3/HIF1α signaling	149
Correction: The circACTN4 interacts with FUBP1 to promote tumorigenesis and progression of breast cancer by regulating the expression of proto-oncogene MYC	148
Nasopharyngeal carcinoma: current views on the tumor microenvironment's impact on drug resistance and clinical outcomes	148
A bispecific Clec9A-PD-L1 targeted type I interferon profoundly reshapes the tumor microenvironment towards an antitumor state	148
Nanomedicine in Cancer Therapeutics: Current Perspectives from Bench to Bedside	148
Correction: Circular RNA-encoded oncogenic PIAS1 variant blocks immunogenic ferroptosis by modulating the balance between SUMOylation and phosphorylation of STAT1	147
Retraction Note: Tetrathiomolybdate inhibits head and neck cancer metastasis by decreasing tumor cell motility, invasiveness and by promoting tumor cell anoikis	146
Correction: Circular RNA ACVR2A suppresses bladder cancer cells proliferation and metastasis through miR-626/EYA4 axis	146
Correction: CircSMARCC1 facilitates tumor progression by disrupting the crosstalk between prostate cancer cells and tumor-associated macrophages via miR-1322/CCL20/CCR6 signaling	146
Enhancing therapeutic anti-cancer responses by combining immune checkpoint and tyrosine kinase inhibition	145
Loss of TACC2 impairs chemokine CCL3 and CCL4 expression and reduces response to anti-PD-1 therapy in soft tissue sarcoma	144
Deubiquitination of CDC6 by OTUD6A promotes tumour progression and chemoresistance	144
DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy	143
Exosome circATP8A1 induces macrophage M2 polarization by regulating the miR-1-3p/STAT6 axis to promote gastric cancer progression	140
Circular RNA circCLASP2 promotes nasopharyngeal carcinoma progression through binding to DHX9 to enhance PCMT1 translation	139
Biologically targeted dual adaptive and innate nano-Immunotherapy for clear cell renal cell carcinoma treatment	138
The application of organoids in treatment decision-making for digestive system cancers: progress and challenges	137

Modeling pediatric low-grade glioma heterogeneity using human forebrain organoids	132
m6A methylation reader IGF2BP2 activates endothelial cells to promote angiogenesis and metastasis of lung adenocarcinoma	132
lncRNAs: the unexpected link between protein synthesis and cancer adaptation	129
Context-dependent impact of type I interferon signaling in cancer	129
A positive feedback loop between PFKP and c-Myc drives head and neck squamous cell carcinoma progression	128
The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancer	126
Identification of multidrug chemoresistant genes in head and neck squamous cell carcinoma cells	125
Targeting cholesterol-driven immunometabolism in cancer: from molecular circuits to clinical translation	124
Capmatinib is an effective treatment for MET-fusion driven pediatric high-grade glioma and synergizes with radiotherapy	122
Metabolic reprogramming and molecular crosstalk at the cancer–endothelial interface in ovarian carcinoma	122
EMT/MET plasticity in cancer and Go-or-Grow decisions in quiescence: the two sides of the same coin?	120
Dissecting small cell carcinoma of the esophagus ecosystem by single-cell transcriptomic analysis	119
CircAKT3 promotes prostate cancer proliferation and metastasis by enhancing the binding of RPS27A and RPL11	117
Functional CRISPR screens in T cells reveal new opportunities for cancer immunotherapies	116
Comprehensive characterization of the prostate tumor microenvironment identifies CXCR4/CXCL12 crosstalk as a novel antiangiogenic therapeutic target in prostate cancer	114
Tumor-associated macrophages: untapped molecular targets to improve T cell-based immunotherapy	114
Molecular mechanisms of tumor resistance to radiotherapy	113
Neuroscience of cancer: unraveling the complex interplay between the nervous system, the tumor and the tumor immune microenvironment	113
Activation-induced cytidine deaminase causes recurrent splicing mutations in diffuse large B-cell lymphoma	112
Acidosis-mediated increase in IFN-γ-induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumors	112
Precision immunotherapy for head and neck cancer: therapeutic combinations, biomarker strategies, and translational challenges	111
Inhibition of 6-phosphogluconate dehydrogenase suppresses esophageal squamous cell carcinoma growth and enhances the anti-tumor effects of metformin via the AMPK/mTOR pathway	111
CDC6 is a prognostic biomarker and correlated with immune infiltrates in glioma	110
CircSMARCC1 facilitates tumor progression by disrupting the crosstalk between prostate cancer cells and tumor-associated macrophages via miR-1322/CCL20/CCR6 signaling	110
Size matters: integrating tumour volume and immune activation signatures predicts immunotherapy response	108
Correction: Long non-coding RNA GBCDRlnc1 induces chemoresistance of gallbladder cancer cells by activating autophagy	106
Correction: MIR22HG acts as a tumor suppressor via TGFβ/SMAD signaling and facilitates immunotherapy in colorectal cancer	106
A PIK3CA-mutant breast cancer metastatic patient-derived organoid approach to evaluate alpelisib treatment for multiple secondary lesions	103
Harnessing the MYB-dependent TAL1 5’super-enhancer for targeted therapy in T-ALL	102
BID expression determines the apoptotic fate of cancer cells after abrogation of the spindle assembly checkpoint by AURKB or TTK inhibitors	100
Retraction Note: Reduced expression of AMPK-β1 during tumor progression enhances the oncogenic capacity of advanced ovarian cancer	99
Deciphering a profiling based on multiple post-translational modifications functionally associated regulatory patterns and therapeutic opportunities in human hepatocellular carcinoma	99
Deciphering the tumor immune microenvironment from a multidimensional omics perspective: insight into next-generation CAR-T cell immunotherapy and beyond	98
Distinct pattern of genomic breakpoints in CML and BCR::ABL1-positive ALL: analysis of 971 patients	98
Multifaceted roles for BCL3 in cancer: a proto-oncogene comes of age	98
Breast cancer immunotherapy: mechanisms of immune evasion, biomarkers, and emerging therapeutic strategies	98
Therapy-induced senescence is a transient drug resistance mechanism in breast cancer	98
Unveiling the PDK4-centered rituximab-resistant mechanism in DLBCL: the potential of the “Smart” exosome nanoparticle therapy	97
A positive feedback circuit driven by m6A-modified circular RNA facilitates colorectal cancer liver metastasis	96
Metabolic checkpoints in immune cell reprogramming: rewiring immunometabolism for cancer therapy	96
Targeting metastasis in paediatric bone sarcomas	95
An exosome-based liquid biopsy signature for pre-operative identification of lymph node metastasis in patients with pathological high-risk T1 colorectal cancer	94
PD1/PD-L1 blockade in clear cell renal cell carcinoma: mechanistic insights, clinical efficacy, and future perspectives	93
Multimodal sequencing of neoadjuvant nivolumab treatment in hepatocellular carcinoma reveals cellular and molecular immune landscape for drug response	92
Present and future of cancer nano-immunotherapy: opportunities, obstacles and challenges	92
Cancer neuroscience in head and neck: interactions, modulation, and therapeutic strategies	91
Co-transcriptional R-loops-mediated epigenetic regulation drives growth retardation and docetaxel chemosensitivity enhancement in advanced prostate cancer	91
Hypoxia-induced lncRNA STEAP3-AS1 activates Wnt/β-catenin signaling to promote colorectal cancer progression by preventing m6A-mediated degradation of STEAP3 mRNA	90
N-glycosylation of PD-L1 modulates the efficacy of immune checkpoint blockades targeting PD-L1 and PD-1	90
OLFM4 promotes the progression of intestinal metaplasia through activation of the MYH9/GSK3β/β-catenin pathway	90
Integrating single cell- and spatial- resolved transcriptomics unravels the inter-tumor heterogeneity and immunosuppressive landscape in HBV- and Clonorchis sinensis-associated hepatocellular carcinom	86
CircKIAA1617 promotes stemness via USP14/PGRMC1-mediated autophagy and lipid metabolism reprogramming in ER-positive breast cancer	85
Intracellular osteopontin protects from autoimmunity-driven lymphoma development inhibiting TLR9-MYD88-STAT3 signaling	84
Retraction Note: Systematic analyses reveal long non-coding RNA (PTAF)-mediated promotion of EMT and invasion-metastasis in serous ovarian cancer	84
BIRC2 blockade facilitates immunotherapy of hepatocellular carcinoma	83
Integration of pan-omics technologies and three-dimensional in vitro tumor models: an approach toward drug discovery and precision medicine	82
PRMT7: a survive-or-die switch in cancer stem cells	82
Beyond the mouse: 3R-guided alternative animal models transforming cancer research	82
Spatiotemporal dynamics of radioresistance: decoding macrophage-driven radioprotective niches through temporal-spatial reprogramming	82
Cross-talk between cancer stem cells and immune cells: potential therapeutic targets in the tumor immune microenvironment	81
Targeting MYC in T-Cell lymphoma via epigenetic modulation with a small-molecule inhibitor	81
Anti irradiation nanoparticles shelter immune organ from radio-damage via preventing the IKK/IκB/NF-κB activation	81
Role of a novel circRNA-CGNL1 in regulating pancreatic cancer progression via NUDT4–HDAC4–RUNX2–GAMT-mediated apoptosis	81
Interleukin-21 receptor signaling promotes metabolic dysfunction-associated steatohepatitis-driven hepatocellular carcinoma by inducing immunosuppressive IgA+ B cells	80
EIF4A3/circPTGR1/miR-4725-5p positive- feedback loop promotes colorectal cancer progression via FAK/AKT signaling pathway	80
Multi-omics profiling uncovers immune-molecular clusters with distinct chemo-immunotherapeutic vulnerabilities in a mouse model of triple-negative breast cancer	79
A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better	79
CircVAPA promotes small cell lung cancer progression by modulating the miR-377-3p and miR-494-3p/IGF1R/AKT axis	79
Correction: Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway	77
Unveiling the immunomodulatory dance: endothelial cells’ function and their role in non-small cell lung cancer	77
Reprogramming anchorage dependency by adherent-to-suspension transition promotes metastatic dissemination	77
Recent advances of small extracellular vesicle biomarkers in breast cancer diagnosis and prognosis	75
Spatiotemporal metabolomic approaches to the cancer-immunity panorama: a methodological perspective	75
Biological and pharmacological roles of m6A modifications in cancer drug resistance	75
Exosomal miR-4745-5p/3911 from N2-polarized tumor-associated neutrophils promotes gastric cancer metastasis by regulating SLIT2	74
Epithelial-to-mesenchymal transition (EMT) and cancer metastasis: the status quo of methods and experimental models 2025	74
Adjuvant recombinant human endostatin combined with toripalimab (anti-PD-1) in locally advanced melanoma: an exploratory phase 2 clinical trial incorporating single-cell RNA/TCR/BCR sequencing	74
Circular RNA-encoded oncogenic PIAS1 variant blocks immunogenic ferroptosis by modulating the balance between SUMOylation and phosphorylation of STAT1	72
A high proportion of germline variants in pediatric chronic myeloid leukemia	72
Identification of HSP90B1 in pan-cancer hallmarks to aid development of a potential therapeutic target	72

Inflammation in cancer: therapeutic opportunities from new insights	72
Proapoptotic activity of JNK-sensitive BH3-only proteins underpins ovarian cancer response to replication checkpoint inhibitors	71
Pangaea Oncology, Dexeus University Hospital: bridging preclinical and clinical research	71
Microbiome-targeted nanoplatforms and engineering approaches in breast cancer therapy	70
Shifting landscapes of gender equity in oncology journals: a decade of authorship trends	70
Correction: Proteogenomic characterization of molecular and cellular targets for treatment‑resistant subtypes in locally advanced cervical cancers	70
Correction: Expression and inactivation of glycogen synthase kinase 3 alpha/ beta and their association with the expression of cyclin D1 and p53 in oral squamous cell carcinoma progression	68
Correction: YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma	68
SELP+ TEC:CD8+ T cell crosstalk associates with improved radiotherapy efficacy in cervical cancer	68
Correction: Acyl-coenzyme a binding protein (ACBP) - a risk factor for cancer diagnosis and an inhibitor of immunosurveillance	68
Retraction Note to: LncRNA PVT1 triggers Cyto-protective autophagy and promotes pancreatic ductal adenocarcinoma development via the miR-20a-5p/ULK1 Axis	68
Cancer stem cell-driven drug resistance in colorectal carcinoma: molecular aspects and therapeutic potentials	67
Combined targeting of GPX4 and BCR-ABL tyrosine kinase selectively compromises BCR-ABL+ leukemia stem cells	67
[18F]FDG PET/CT multiomics identifies Hedgehog-driven HPV-negative head and neck squamous cell carcinoma	67
Exploring molecular and cellular mechanisms of Pre-Metastatic niche in renal cell carcinoma	67
YTHDF2 in peritumoral hepatocytes mediates chemotherapy-induced antitumor immune responses through CX3CL1-mediated CD8+ T cell recruitment	67
Combined inhibition of Bcl-2 family members and YAP induces synthetic lethality in metastatic gastric cancer with RASA1 and NF2 deficiency	67
A comprehensive overview of ovarian cancer stem cells: correlation with high recurrence rate, underlying mechanisms, and therapeutic opportunities	66
Chimeric antigen receptor macrophages targeting c-MET(CAR-M-c-MET) inhibit pancreatic cancer progression and improve cytotoxic chemotherapeutic efficacy	66
Deciphering resistance mechanisms in cancer: final report of MATCH-R study with a focus on molecular drivers and PDX development	66
Lysyl hydroxylase LH1 promotes confined migration and metastasis of cancer cells by stabilizing Septin2 to enhance actin network	65
CircHERC1 promotes non-small cell lung cancer cell progression by sequestering FOXO1 in the cytoplasm and regulating the miR-142-3p-HMGB1 axis	65
Spatially-resolved subtype progression reveals metabolic vulnerabilities in pancreatic ductal adenocarcinoma	65
CBFA2T2: a novel H3K27 reader regulating metabolism and tumor growth	65
Lung-specific metastasis: the coevolution of tumor cells and lung microenvironment	64
Tumor metabolic regulators: key drivers of metabolic reprogramming and the promising targets in cancer therapy	64
Single-cell RNA sequencing reveals immune microenvironment niche transitions during the invasive and metastatic processes of ground-glass nodules and part-solid nodules in lung adenocarcinoma	64
Cuproptosis correlates with immunosuppressive tumor microenvironment based on pan-cancer multiomics and single-cell sequencing analysis	63
Exploiting innate immunity for cancer immunotherapy	63
Circular RNA ACVR2A promotes the progression of hepatocellular carcinoma through mir-511-5p targeting PI3K-Akt signaling pathway	63
Circular RNA circPOLR2A promotes clear cell renal cell carcinoma progression by facilitating the UBE3C-induced ubiquitination of PEBP1 and, thereby, activating the ERK signaling pathway	63
Overcoming resistance to anti-PD-L1 immunotherapy: mechanisms, combination strategies, and future directions	63
Clustering cancers by shared transcriptional risk reveals novel targets for cancer therapy	62
Next-generation CAR-T cells design: leveraging tumor features for enhanced efficacy	62
Essential gene screening identifies the bromodomain-containing protein BRPF1 as a new actionable target for endocrine therapy-resistant breast cancers	62
i-CRISPR: a personalized cancer therapy strategy through cutting cancer-specific mutations	62
Immune dynamics shaping pre-metastatic and metastatic niches in liver metastases: from molecular mechanisms to therapeutic strategies	62
Single-cell RNA-seq reveals the genesis and heterogeneity of tumor microenvironment in pancreatic undifferentiated carcinoma with osteoclast-like giant-cells	62
Combined proteomics and CRISPR‒Cas9 screens in PDX identify ADAM10 as essential for leukemia in vivo	61
Diagnostic leukapheresis reveals distinct phenotypes of NSCLC circulating tumor cells	61
Correction: The circROBO1/KLF5/FUS feedback loop regulates the liver metastasis of breast cancer by inhibiting the selective autophagy of afadin	61
The circSPON2/miR-331-3p axis regulates PRMT5, an epigenetic regulator of CAMK2N1 transcription and prostate cancer progression	60
Multifunctional chitosan–doxorubicin nanocarriers: advancing targeted breast cancer chemotherapy	60
Circulating cell-free DNA methylation patterns as non-invasive biomarkers to monitor colorectal cancer treatment efficacy without referencing primary site mutation profiles	60
STING-Activating nanoplatforms for image-guided sonodynamic cancer therapy	60
Retraction Note: Quercetin-induced miR-200b-3p regulates the mode of self-renewing divisions in pancreatic cancer	60
PDGFRβ promotes oncogenic progression via STAT3/STAT5 hyperactivation in anaplastic large cell lymphoma	60
Immunoproteasome function maintains oncogenic gene expression in KMT2A-complex driven leukemia	59
CircRNA aptamer targets IGF2BP2 to overcome acquired BETi resistance	59
Expression of mTOR in normal and pathological conditions	59
Skin cancer: understanding the journey of transformation from conventional to advanced treatment approaches	58
Hijacking of the nervous system in cancer: mechanism and therapeutic targets	58
A prospective multi-cohort study identifies and validates a 5-gene peripheral blood signature predictive of immunotherapy response in non-small cell lung cancer	58
Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T	57
LINE-1 promotes tumorigenicity and exacerbates tumor progression via stimulating metabolism reprogramming in non-small cell lung cancer	57
c-Rel drives pancreatic cancer metastasis through fibronectin-integrin signaling-induced isolation stress resistance and EMT	57
Targeting m7G-enriched circKDM1A prevents colorectal cancer progression	56
Wnt signaling in cancer: from biomarkers to targeted therapies and clinical translation	56
Lactate: elucidating its indispensable role in human health	56
Extracellular vesicles in tumor immunity: mechanisms and novel insights	55
The application of organoids in investigating immune evasion in the microenvironment of gastric cancer and screening novel drug candidates	55
Mapping cancer biology in space: applications and perspectives on spatial omics for oncology	55
Correction: circCYP24A1 facilitates esophageal squamous cell carcinoma progression through binding PKM2 to regulate NF-κB-induced CCL5 secretion	54
The University of Kansas Cancer Center (KUCC), an NCI designated comprehensive cancer center	54
Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer	54
Lipid nanoparticles deliver DNA-encoded biologics and induce potent protective immunity	54
Correction: ZEB1 transcriptionally regulated carbonic anhydrase 9 mediates the chemoresistance of tongue cancer via maintaining intracellular pH	54
Commentary on “Intercellular TIMP-1-CD63 signaling directs the evolution of immune escape and metastasis in KRAS-mutated pancreatic cancer cells”	53
Mechanism of ERBB2 gene overexpression by the formation of super-enhancer with genomic structural abnormalities in lung adenocarcinoma without clinically actionable genetic alterations	53
Transfer RNA-derived small RNAs in tumor microenvironment	53
HPGD induces ferroptosis and autophagy to suppress esophageal squamous cell carcinoma through the LXA4–ERK1/2–U2AF2–TFRC axis	52
circASAP1 induces renal clear cell carcinoma ferroptosis by binding to HNRNPC and thereby regulating GPX4	52
The epigenetic hallmarks of immune cells in cancer	52
Deciphering the role of LGALS2: insights into tertiary lymphoid structure-associated dendritic cell activation and immunotherapeutic potential in breast cancer patients	51
Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop	51
CAR T cells: engineered immune cells to treat brain cancers and beyond	51
A microRNA signature for risk-stratification and response prediction to FOLFOX-based adjuvant therapy in stage II and III colorectal cancer	51
Mir-483-5p-mediated activating of IGF2/H19 enhancer up-regulates IGF2/H19 expression via chromatin loops to promote the malignant progression of hepatocellular carcinoma	51
Correction: Comprehensive review of CRISPR‑based gene editing: mechanisms, challenges, and applications in cancer therapy	51
Downregulation of Sod2 increases atypical flat lesions and dysplasia to advance pancreatic ductal adenocarcinoma	51
The single cell transcriptional landscape of esophageal adenocarcinoma and its modulation by neoadjuvant chemotherapy	50
Metabolic reprogramming in cancer: signaling pathways and therapeutic targets	50
The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRASG12D-driven non-small cell lung cancer	50
Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy	50
Traditional Chinese medicine in the treatment of breast Cancer	50
Evolution of direct RAS inhibitors: from undruggable target to clinical breakthroughs	49
PROTAC’ing oncoproteins: targeted protein degradation for cancer therapy	49
Writers, readers, and erasers RNA modifications and drug resistance in cancer	48
Lipid reprogramming and ferroptosis crosstalk in clear cell renal cell carcinoma: metabolic vulnerabilities and therapeutic targeting	48
The journey of CAR-T therapy in hematological malignancies	48
​​The immune microenvironment of pathogen-associated cancers and current clinical therapeutics	48
Clinical application of liquid biopsy in colorectal cancer: detection, prediction, and treatment monitoring	48
The mycobiome in human cancer: analytical challenges, molecular mechanisms, and therapeutic implications	48
Mechanisms and cross-talk of regulated cell death and their epigenetic modifications in tumor progression	48
Ferroptosis in cancer toward molecular insights and clinical translation in pancreatic cancer	47